장대영 교수
전문진료분야
위, 대장, 간, 췌장, 담도, GIST 소화기암, 만성백혈병, 골수이형성증 등 혈액질환
전화 예약
1577-1801
기본정보
학력
한림대학교 의과대학 의학박사(MD, Ph.D) |
경력
현) 한림대학교의료원 중앙임상의학연구소 소장 현) 한림대학교성심병원 임상시험센터장 Weil Cornell Cancer Center, New York, USA, Visiting Professor FHCRC, Research Associate, Seattle, USA 서울아산병원 종양혈액내과 임상강사 |
학회활동
현) 대한항암요법연구회(KCSG) 회장, 이사회의장 현) 대한임상시험센터협의회(KACTC) 회장 대한위암학회 현)상임이사 대한종양내과학회 현)윤리위원장, 기획이사 대한혈액학회 교육수련이사, 사회봉사교육이사 과기부 생명공학연구원 현)바이오규제위원 국가항암신약개발사업단 현)자문위원 국민건강보험공단 현)약제급여평가위원, 현)산정특례위원 대한암학회 건강보험정책위원장 식품의약품안전처 현)항암제전략자문위원, 현)중앙약사심의위원, 현)심속심의자문위원 건강보험심사평가원 현)암질환심의위원 |
수상이력
미국혈액학회 우수논문상 한림대학교 학술상 |
논문
Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer (British Journal of Cancer)
Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer (British Journal of Cancer, (2025), 133, 2, (208-215), 10.1038/s41416-025-03052-y) (British Journal of Cancer)
Population Pharmacokinetic Modeling of Piperacillin/Tazobactam in Healthy Adults and Exploration of Optimal Dosing Strategies (PHARMACEUTICALS)
Predictive Value of the nProfiler 1 Assay for the Efficacy of Adjuvant S-1？Based Doublet Chemotherapy in Stage III Gastric Cancer: A Post-Hoc Analysis of a Randomized Phase III Trial (Cancer Research and Treatment)
Association between Tumor Size at the Time of Disease Progression and Survival Outcomes (Cancer Research and Treatment)
Development of a Population Pharmacokinetic Model of Levofloxacin in Healthy Adults and Identification of Optimal Dosing Regimens (PHARMACEUTICALS)
The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group (Cancer Research and Treatment)
Predictive Value of the nProfiler 1 Assay for the Efficacy of Adjuvant S-1-Based Doublet Chemotherapy in Stage III Gastric Cancer: A Post-Hoc Analysis of a Randomized Phase III Trial / ^^영문 제목을 반드시 기재하시기 바랍니다. (Cancer research and treatment)
Varlitinib and Paclitaxel for EGFR/HER2 Co-Expressing Advanced Gastric Cancer: a Multicenter Phase Ib/II Study (K-MASTER-13) (Cancer Research and Treatment)
Association between Tumor Size at the Time of Disease Progression and Survival Outcomes / ^^영문 제목을 반드시 기재하시기 바랍니다. (Cancer research and treatment)
위암과 위장관 질환 (군자출판사)
혈액학 (범문에듀케이션)
위암 임상진료지침 (한국임상암학회)
위암표준진료권고안 (대한의학회)
환우와 가족을 위한 혈액 질환 소개서 (대한혈액학회)
혈액학 / Hematology ((주)범문에듀케이션)
RECTAL CANCER-a multidisciplinary approach to management (Intech)
혈액학 / hematology (E*public)
Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer (British Journal of Cancer, (2025), 133, 2, (208-215), 10.1038/s41416-025-03052-y) (British Journal of Cancer)
Population Pharmacokinetic Modeling of Piperacillin/Tazobactam in Healthy Adults and Exploration of Optimal Dosing Strategies (PHARMACEUTICALS)
Predictive Value of the nProfiler 1 Assay for the Efficacy of Adjuvant S-1？Based Doublet Chemotherapy in Stage III Gastric Cancer: A Post-Hoc Analysis of a Randomized Phase III Trial (Cancer Research and Treatment)
Association between Tumor Size at the Time of Disease Progression and Survival Outcomes (Cancer Research and Treatment)
Development of a Population Pharmacokinetic Model of Levofloxacin in Healthy Adults and Identification of Optimal Dosing Regimens (PHARMACEUTICALS)
The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group (Cancer Research and Treatment)
Predictive Value of the nProfiler 1 Assay for the Efficacy of Adjuvant S-1-Based Doublet Chemotherapy in Stage III Gastric Cancer: A Post-Hoc Analysis of a Randomized Phase III Trial / ^^영문 제목을 반드시 기재하시기 바랍니다. (Cancer research and treatment)
Varlitinib and Paclitaxel for EGFR/HER2 Co-Expressing Advanced Gastric Cancer: a Multicenter Phase Ib/II Study (K-MASTER-13) (Cancer Research and Treatment)
Association between Tumor Size at the Time of Disease Progression and Survival Outcomes / ^^영문 제목을 반드시 기재하시기 바랍니다. (Cancer research and treatment)
위암과 위장관 질환 (군자출판사)
혈액학 (범문에듀케이션)
위암 임상진료지침 (한국임상암학회)
위암표준진료권고안 (대한의학회)
환우와 가족을 위한 혈액 질환 소개서 (대한혈액학회)
혈액학 / Hematology ((주)범문에듀케이션)
RECTAL CANCER-a multidisciplinary approach to management (Intech)
혈액학 / hematology (E*public)